Main Uses and Therapeutic Indications

Destolit contains ursodeoxycholic acid, a naturally occurring bile acid found in small quantities in human bile. It is primarily used to manage conditions affecting the gallbladder and the liver's biliary system.

Dissolution of Gallstones

One of the primary uses of Destolit is for the dissolution of specific types of gallstones. It is effective against small stones made primarily of cholesterol that are radiolucent, meaning they do not show up on a standard X-ray. This treatment is generally considered when the stones are not large enough to require surgery or when surgical intervention is not suitable for the patient.

Primary Biliary Cholangitis (PBC)

Destolit is used in the management of Primary Biliary Cholangitis, a chronic liver disease where the bile ducts in the liver are slowly destroyed. By supplementing the body's bile acid pool, the medication helps to protect liver cells from the secondary damage caused by the accumulation of more toxic bile acids, potentially slowing the progression of the disease.

Benefits and Mechanism of Action

Reduction of Cholesterol Saturation

Destolit works by reducing the amount of cholesterol secreted into the bile by the liver. It also helps to disperse the cholesterol from existing stones, allowing them to gradually dissolve over time. This process helps restore a healthier balance of bile components.

Cytoprotective Effects

In chronic cholestatic liver diseases, the medication provides a cytoprotective effect. It replaces detergent-like, toxic bile acids with ursodeoxycholic acid, which is less harmful to cell membranes. This shift helps to reduce inflammation and stabilize liver function markers.

Symptomatic Improvement

For patients with chronic biliary issues, the treatment may lead to a reduction in symptoms associated with impaired bile flow. By improving the flow of bile through the liver and gallbladder, it supports the overall digestive process and reduces the metabolic stress on liver tissues.

Regulatory References

1. NIH MedlinePlus overview on Ursodiol

Destolit (ursodeoxycholic acid) is a medicine that is not suitable for all patients. Official regulatory documents define specific populations and conditions where its use is restricted or strictly prohibited.

---

Contraindicated Populations (Must NOT Use)

Use of Destolit is contraindicated (prohibited) in patients with:

• Hypersensitivity to the active substance or bile acids.
• Acute inflammation of the gallbladder or biliary tract.
• Occlusion or blockage of the biliary tract (e.g., common bile duct or cystic duct).
• Radio-opaque calcified gallstones or an impaired contractility of the gallbladder.
• Active gastric or duodenal ulcer or inflammatory bowel disease.
• Acute, chronic, or severe liver disease, or those in the final stage of primary biliary cholangitis/cirrhosis.
• Children with disrupted biliary drainage due to biliary atresia where bile flow is not restored.

---

Special Eligibility Rules

• Pregnancy and Lactation: The medicine must not be used during pregnancy unless deemed clearly necessary. Women of childbearing potential must use reliable non-hormonal contraception (or low-estrogen oral contraceptives).
• Age-Related Eligibility: While generally used in adults and the elderly, use in the paediatric population is only officially established for children aged 6 years to less than 18 years to treat hepatobiliary disorders associated with cystic fibrosis.

Interactions with Other Medicines and Products

The interaction profile for Destolit (Ursodiol) is defined by officially documented patterns that impact efficacy, absorption, and plasma concentrations of other medicines. This information is based on regulatory prescribing documents.

Interactions that Reduce Destolit’s Effectiveness

Certain medicines and dietary factors may counteract Destolit’s intended effects, especially when used for gallstone dissolution. Hormonal Oral Contraceptive Agents and Oestrogenic Hormones are officially discouraged, as they increase cholesterol secretion in bile. The same caution applies to Clofibrate and similar lipid-lowering drugs. Additionally, consuming excessive dietary cholesterol and calories is noted to reduce the drug's efficacy.

Interactions Affecting Drug Absorption

The absorption of Destolit is reduced by Bile Acid Sequestering Agents (e.g., Cholestyramine) and Antacids containing Aluminum Hydroxide. Regulatory guidelines mandate that these substances must be taken at least two hours before or after Destolit to prevent a loss of therapeutic benefit.

Altered Exposure of Co-administered Medicines

Ursodiol alters the plasma concentrations of certain co-administered drugs. Regulatory data indicates that Ursodiol can increase the absorption and serum levels of the immunosuppressant Ciclosporin. Conversely, Ursodiol has been documented to reduce the plasma exposure (Cmax and AUC) of the calcium antagonist Nitrendipine and the therapeutic effect of Dapsone. The regulatory conclusion is that Destolit does not have a relevant inductive effect on cytochrome P450 3A enzymes.

Specific Restrictions

Female patients using Destolit for gallstone dissolution must use effective non-hormonal contraception due to the officially noted counter-effect of hormonal agents.

The active component, Ursodiol (Ursodeoxycholic acid), exerts its action through three fundamental mechanistic domains that modify the composition and flow dynamics of bile and influence the cellular stability of the biliary system.

Chemical Modification and Desaturation of Bile

This mechanism acts on the balance of components within the bile fluid by inhibiting the secretion of cholesterol from the liver and suppressing its intestinal absorption. This action leads to a direct desaturation of the bile, reducing the concentration of solid cholesterol. The resulting physiological effect is a lowered tendency of the bile to precipitate and aggregate, which chemically prevents the formation and aggregation of crystals.

Cellular Stabilization and Toxic Bile Acid Displacement

Ursodiol is a more hydrophilic bile acid that operates by competitively displacing the endogenous, more hydrophobic bile acids from the circulating pool. Furthermore, it incorporates directly into the cell and mitochondrial membranes of liver and bile duct cells. This displacement and structural stabilization reduces the impact of the detergent-like damage and anti-apoptotic properties of the more toxic bile acids, contributing to the maintenance of hepatic tissue integrity.

Choleresis and Enhanced Bile Flow Dynamics

The drug promotes choleresis by stimulating the activity of key membrane transport proteins on the cell surface of the bile ducts, such as the Anion Exchanger 2 (AE2). This modulation of membrane transport enhances the secretion of ions and water into the bile ductules. The resulting physiological consequence is a measurable increase in bile volume and flow rate, which facilitates the transport of the chemically modified bile through the biliary system.

Administration Guidelines for Destolit (Ursodiol)

Destolit is a prescription-only bile acid preparation administered strictly via the oral route. Its usage protocol is dependent on the approved indication and is defined by the following instructions:

Usage Aspect	Standard Administration Protocol
Dosing Schedule	Dosage is typically calculated based on body weight (8-15 mg/kg per day) rather than a fixed standard dose. The total daily amount may be adjusted by the prescribing clinician.
Frequency & Timing	Initial use often requires the total daily dose to be split into two to four divided doses. For long-term maintenance or gallstone dissolution, the dose is frequently consolidated to a single administration taken in the evening.
Administration Condition	The medicine should be taken with food or immediately after meals to optimize absorption. Tablets and capsules must be swallowed whole with water.
Duration Pattern	Use for gallstone dissolution is typically capped at two years, requiring continued administration for up to several months after stones vanish. Use for Primary Biliary Cholangitis is often part of an indefinite, long-term plan.
Special Populations	Pediatric dosing is documented for specific hepatobiliary disorders (e.g., up to 30 mg/kg/day divided). Dose adjustment for older adults is generally not required.
Missed Dose Rule	Patients are instructed not to take a double dose to compensate for a forgotten one. Administration should resume at the next scheduled time.

These guidelines define the standardized administration method, ensuring the dose is individualized by weight, precisely timed in relation to food, and taken regularly for the entire duration mandated by the regimen.

Research Evidence / Overview of Studies for Destolit

---

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research examining the role of Destolit in long-term disease patterns in Primary Biliary Cholangitis (PBC) primarily involves Randomized Controlled Trials (RCTs) and meta-analyses. Researchers used these study designs to explore the medicine's role and various laboratory measurements. The populations studied were adult patients with PBC, including those with varying levels of disease activity.

Studies reported patterns of measured change in key liver biochemistry markers, such as Alkaline Phosphatase (ALP) and Bilirubin levels, which are routinely used as indicators of liver health. Findings from extended follow-up phases and observational cohorts suggested an association between the use of the medicine and findings related to the measured endpoint of transplant-free survival free from liver transplantation or death, particularly in patients who began treatment earlier in the disease course. Research highlights that these findings contribute to the understanding of symptom patterns over time.

However, the evidence remains limited and heterogeneous in certain areas. Although there were reported changes in biochemical markers, research has provided limited insight into whether the medicine is associated with patient-reported outcomes related to symptoms like chronic fatigue and itching. Additionally, studies have consistently noted that up to 40% of the patient population does not achieve the expected change in biochemical markers, and data for optimal management in this specific group are still emerging.

---

Evidence for Use in Dissolving Cholesterol Gallstones

The evidence base for using the medicine to dissolve cholesterol gallstones primarily comes from Clinical Trials and subsequent Long-term Follow-up Studies. These studies were applied in highly specific patient-reported experiences where individuals had small (typically less than 20 millimeters), non-calcified, cholesterol-based gallstones and a functioning gallbladder. The main outcomes measured included the rate of complete gallstone dissolution (total disappearance of stones) and the subsequent rate of gallstone recurrence.

Findings indicate that complete dissolution was an observed pattern in a subset of the highly selected patients observed in the trials. The research describes patterns where the observed rate of dissolution was highest for those with very small stones. These dissolution attempts involved follow-up periods over an extended duration, sometimes up to two years, in the research.

What remains uncertain is the long-term stability of the stone-free status. Studies that monitored patients after dissolution reported a frequent pattern of gallstone reappearance, with recurrence rates associated with up to 50% of patients within five years. This research highlights that observed outcomes apply only to the specific populations studied (small, non-calcified stones), and data are insufficient for the effectiveness in patients with larger or calcified stones.

---

Evidence for Research Exploring New Gallstone Formation

Research exploring the medicine's role in research exploring new gallstone formation was primarily conducted using Randomized Controlled Trials (RCTs) against a placebo. These studies focused on populations experiencing rapid weight loss, such as those undergoing bariatric surgery, who are known to be at a higher risk of forming new gallstones. The outcomes monitored included the incidence rate of new stone formation (verified by imaging) and the need for subsequent surgical removal.

Studies reported an observed difference in the incidence rate of new gallstone formation between the groups receiving the medicine and the placebo groups during the initial period of rapid weight loss. Research describes that this pattern was consistent across several controlled settings. This evidence contributes to the broader evidence landscape related to the outcomes reflecting daily functioning or activity level during a period of significant body change.

Follow-up durations were limited in many of these primary studies, focusing mostly on the first six to twelve months post-procedure, which is the window of most rapid weight reduction. Long-term effects are not fully established regarding the incidence of stone formation or recurrence in the years following the cessation of the prophylactic regimen, and comparative evidence is lacking for the effects in all types of rapid weight loss scenarios.

---

Long-Term Research and Durability of Response

Studies monitoring patients with PBC over defined time intervals that extend many years described an association between continuous treatment and improved long-term transplant-free survival. These findings, derived from open-label extensions of initial trials and large registries, help contextualize how patients reported their experience over long periods.

In contrast, the long-term research for gallstone dissolution describes a significant limitation regarding the long-term stability of the stone-free status. Studies monitored the recurrence rates and found that, despite initial dissolution, gallstones were associated with a high rate of reappearance in the years following. Research highlights changes measured during the short-term study period, but long-term effects are not fully established for maintaining a stone-free status.

---

Research in Specific Patient Groups

The research has primarily been conducted in adult populations with PBC or candidates for gallstone treatment. Data for certain groups remain insufficient. For instance, while some studies included patients with varying degrees of PBC severity, the evidence quality varies across studies when examining outcomes in the most advanced stages of liver disease.

Specific data for pediatric populations (children and adolescents) are not as extensive as those for adults, and research highlights that the results apply only to the populations studied and research is not immediately applicable to these younger groups. Similarly, research exploring the use of the medicine in populations with other coexisting conditions is often restricted or insufficient to draw broad conclusions.

---

What Remains Uncertain in the Research

Research provides context but not individual predictions, and several areas remain where certainty remains low or where more studies are exploring the full scope of the medicine's influence.

• Symptom Relief: Despite clear findings related to liver markers in PBC, the research has limited information on how the medicine affects common patient-reported outcomes describing perceived discomfort related to chronic symptoms like fatigue and pruritus (itching). Findings were mixed across studies for these outcomes.
• Optimal Duration and Non-Responders: For PBC, up to 40% of patients are documented as not achieving the desired change in biochemical markers; the subgroup findings are uncertain regarding other research pathways for this population.
• Long-Term Follow-up: While studies have been observed in settings with varying symptom burdens, comparative evidence is lacking to fully establish the long-term evidence on stopping or continuing treatment in various treatment scenarios, particularly after the successful prevention or dissolution of gallstones.

Key Studies & References

1. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

Common questions about Destolit (FAQ)

Q: How does Destolit work to treat gallstones?

According to official regulatory documents, the medicine works by affecting the chemistry of bile. It functions by inhibiting the liver’s secretion of cholesterol and reducing its absorption from the intestine. This action is associated with the desaturation of bile and helps to create conditions for the dissolution of cholesterol-rich gallstones.

Q: Is it true that Destolit is not approved by the FDA for all its uses?

The specific approved indications for the medicine, such as the treatment of Primary Biliary Cholangitis (PBC) or the dissolution of gallstones, can differ depending on the regulatory authority overseeing approval (such as the FDA in the US or the EMA in Europe). Official guidance indicates patients may refer to the official labeling for the indication they are being treated for.

Q: How long does it typically take for Destolit to dissolve gallstones?

Clinical studies indicate that initial response for gallstone dissolution can begin within three to six months of starting treatment. However, achieving complete dissolution of the stones typically requires continuous administration for an extended period, sometimes up to two years.

Q: What happens after the gallstones have dissolved?

Official administration information states that treatment is often recommended to continue for an additional period after the gallstones have been confirmed to be completely dissolved by imaging. This continuation is documented to help maintain the stone-free status for a time.

Q: Is Destolit therapy typically a long-term treatment?

The required duration of Destolit therapy is dependent on the treated condition. For the dissolution of gallstones, treatment is typically limited to two years. Conversely, for conditions such as Primary Biliary Cholangitis (PBC), the medication is generally intended to be part of an indefinite, long-term treatment plan.

Q: Is there a need to follow any specific dietary restrictions while taking Destolit?

Official information indicates that consuming excessive dietary cholesterol and calories can potentially reduce the medicine’s intended effectiveness. This observation suggests that certain dietary choices may counteract the drug's action.

Q: Is it possible for gallstones to come back after taking Destolit?

Studies examining the long-term stability of stone-free status have reported a high rate of recurrence. Official data indicates that gallstones were observed to reappear in up to 50% of patients within five years after treatment for dissolution is stopped.

Q: Can Destolit affect my sleep?

The official safety profile does not commonly list sleep disturbance as an adverse effect. However, regulatory documents do include related neurological symptoms, such as headache and dizziness, in the side effect profile at a frequency that is not precisely known.

Q: Why is regular monitoring of liver enzyme levels recommended during Destolit therapy?

Regulatory warnings indicate that routine monitoring of liver function tests is essential during therapy. This practice is necessary to assess the patient's response to the treatment, check for any signs of potential liver-related safety concerns, and detect any clinical worsening of the underlying condition.

Q: What is the recommendation for using Destolit during pregnancy or while breastfeeding?

Official guidelines state that the medicine is not recommended for use during pregnancy unless the supervising clinician determines a clear medical necessity. For breastfeeding, the amount of the active ingredient that transfers into breast milk is considered very low and is not expected to cause adverse effects in an infant.

Q: What are the signs of a possible allergic reaction to the drug?

Official safety documents classify hypersensitivity reactions among the possible adverse effects. Signs of a possible allergic reaction to the drug may include the appearance of a rash, hives, or swelling of the face, lips, tongue, or throat, or having difficulty breathing.

Q: Is Destolit appropriate for people with non-functioning gallbladders?

Official prescribing information indicates that the medicine is contraindicated (prohibited) if the gallbladder is non-functional or has impaired contractility. Official guidelines state that a functioning gallbladder is considered necessary for the medicine to be effective for gallstone dissolution.

Q: Can children or teenagers take Destolit?

The use of this medicine in younger populations is limited by official regulatory guidelines. Use is officially established only for children aged 6 years to less than 18 years to treat specific hepatobiliary disorders associated with cystic fibrosis.

Q: Are there concerns about taking Destolit with inflammatory bowel conditions?

The medicine is contraindicated (prohibited) in patients who have active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, as documented in official regulatory guidelines.

Q: What does it mean for a gallstone to be 'radiolucent'?

In the context of the medicine, a radiolucent gallstone is defined as one predominantly composed of cholesterol that is non-calcified. This characteristic is typically required for the medicine to be considered appropriate for treatment.

Q: Are there any rare adverse effects reported, such as a worsening of pre-existing conditions?

A very rare but serious adverse event reported in the regulatory documentation is the decompensation of hepatic cirrhosis. This has been reported in patients with advanced Primary Biliary Cholangitis (PBC).

Q: What is the estimated half-life of the active component in Destolit?

Pharmacokinetic data available in official prescribing information shows that the half-life of the active ingredient in the bile acid pool is approximately 3.5 to 5.8 days.

Q: What does the term 'cholestasis' mean in the context of Destolit's use?

Cholestasis is a medical term used to describe a condition in which the release or flow of bile from the liver is reduced, interrupted, or completely blocked. Destolit is used to manage certain conditions associated with compromised bile flow.

Q: Why is it generally advised to take Destolit with or after food?

Regulatory administration guidelines advise taking the medicine with food or immediately after meals. This practice is recommended because taking it with food helps to optimize the body's absorption of the active ingredient.

Q: What are the known limitations of Destolit in terms of treating gallstones?

Official documents describe several limitations for the treatment of gallstones. The medicine is only indicated for small, non-calcified, cholesterol-based gallstones (typically less than 20 mm). The medicine also requires that the patient's gallbladder is still functioning.

Q: How quickly does the body start to absorb the active ingredient in Destolit?

Pharmacokinetic studies indicate that the active ingredient is absorbed rapidly. It typically reaches its peak concentration in the bile fluid between 1 and 3 hours after a dose is taken orally.

Q: What does research indicate about the long-term outcomes for patients taking Destolit?

Long-term studies for Primary Biliary Cholangitis (PBC) have shown an association with outcomes related to transplant-free survival. In contrast, for gallstone dissolution, research indicates that long-term stability is low due to frequent stone recurrence.

Official Storage Conditions

Destolit (ursodiol) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions for transport up to 30 C. The tablets or capsules must be kept in the original container, tightly closed, and stored in a cool, dry area protected from light and excess moisture, such as the bathroom.

Handling and Child Safety

For products where tablets are scored, separated half-tablets must be used within 28 days and should be stored separately from whole tablets due to their bitter taste. It is mandatory to Keep this medication out of the sight and reach of children by using safety caps and storing it in a secure location.

Disposal Requirements

Expired or unused Destolit should not be disposed of via wastewater or household trash. Patients are instructed to utilize official channels, such as a drug take-back program or by consulting a pharmacist, to ensure proper environmental disposition of the medicine.